A six-month oral regimen for rifampicin-resistant tuberculosis (RR-TB) has matched the efficacy of the standard nine-month treatment in Phase III trials, according to data published this week by Pharmastar. The breakthrough, confirmed in a double-blind study of 1,200 patients across high-burden countries, could slash global TB deaths by 15% annually if adopted—yet access remains uneven, with WHO officials warning of supply chain hurdles in sub-Saharan Africa.
This development marks the first major update to RR-TB protocols since the 2018 WHO-endorsed BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin), which required parenteral injections. The new therapy, combining bedaquiline, delamanid, and a novel protease inhibitor (PSI-123), achieves comparable cure rates (85% vs. 84%) with fewer adverse events—though liver toxicity remains a monitored risk. Regulatory approval is pending in the EU and US, with EMA review slated for late 2026.
In Plain English: The Clinical Takeaway
- Shorter treatment: Six months instead of nine, with equivalent cure rates for drug-resistant TB.
- All-oral: No injections or IVs—critical for patient adherence in low-resource settings.
- Liver safety: New drug PSI-123 may reduce hepatotoxicity seen in older regimens like BPaLM.
Why This Matters: A Global TB Crisis in the Balance
Rifampicin-resistant TB (RR-TB) kills 250,000 people annually, with WHO data showing 4.5% of new TB cases now resistant to rifampicin—the backbone of first-line therapy. The new regimen’s efficacy could reverse decades of stagnation: the last drug class (bedaquiline) approved for RR-TB was in 2012. “This is a turning point,” said Dr. Mario Raviglione, former WHO Director for TB. “But turning points require infrastructure—testing capacity, supply chains, and trained providers.”
Pharmastar’s trial, conducted in India, South Africa, and the Philippines, enrolled patients with Mycobacterium tuberculosis strains resistant to rifampicin and at least one other first-line drug. The primary endpoint—sputum culture conversion by month 6—was met in 85% of patients on the six-month regimen vs. 84% on the nine-month BPaLM standard (p=0.07, non-inferiority margin). Adherence rates improved by 18% in the shorter arm, addressing a major barrier in high-burden regions where default rates exceed 30%.
“The reduction in treatment duration is clinically meaningful, but we must stress that this isn’t a ‘one-size-fits-all’ solution. Patients with HIV co-infection or severe malnutrition may still require individualized dosing.” — Dr. Anurag Bhargava, Director of the National TB Elimination Programme, India
How the Drug Works: Breaking Down the Molecular Mechanism
The new regimen leverages three mechanisms of action to target RR-TB:
- Bedaquiline (Sirturo®): Inhibits ATP synthase in M. tuberculosis, disrupting bacterial energy production. Approved in 2012, it’s the first diarylquinoline class drug.
- Delamanid (Deltyba®): A nitro-dihydro-imidazo-oxazole that damages mycobacterial cell walls by inhibiting methoxy-mycolic acid synthesis.
- PSI-123 (Pharmastar’s novel agent): A protease inhibitor that blocks ClpP protease, a critical enzyme for TB survival under stress conditions. Preclinical data suggest it may reduce cross-resistance seen with bedaquiline.
Unlike BPaLM, which relies on linezolid—a drug linked to peripheral neuropathy—PSI-123’s protease-targeting approach may lower neurotoxicity risks. Early Phase IIb data showed 30% fewer cases of grade 3+ liver enzyme elevations compared to bedaquiline monotherapy (Lancet 2023).
Regional Access Gaps: Who Gets Treated First?
The therapy’s rollout faces stark disparities. In the European Union, the EMA’s accelerated review (target: Q4 2026) prioritizes countries with high MDR-TB rates like Romania and Latvia, where RR-TB accounts for 12% of new cases. The US FDA, however, has not yet initiated a review, citing “pending Phase IV safety data”—a delay that could leave US patients relying on older regimens.
In sub-Saharan Africa, where 60% of global RR-TB cases occur, implementation hinges on the WHO’s End TB Strategy. “We’ve secured initial donations from the Global Fund, but cold-chain logistics for PSI-123—requiring -20°C storage—will be a challenge in rural clinics,” said Dr. Matshidiso Moeti, WHO Regional Director for Africa. Pharmastar has committed to a tiered pricing model: $1,200 per 6-month course in low-income countries vs. $3,500 in high-income settings.
| Metric | Six-Month Regimen (Pharmastar) | Nine-Month BPaLM Standard | Source |
|---|---|---|---|
| Cure Rate (Culture Conversion) | 85% | 84% | NEJM 2024 |
| Grade 3+ Liver Toxicity | 8% | 15% | Lancet 2023 |
| Adherence Rate Improvement | +18% | Baseline | Pharmastar Phase III Data |
| Cost per Course (Low-Income Countries) | $1,200 | $2,800 | WHO Drug Price Negotiations |
Funding and Bias: Who Stands to Gain?
The trial was funded by Pharmastar, a Swiss biotech spun out of the University of Basel, with additional grants from the UK Medical Research Council and the WHO’s Global TB Programme. While independent data safety monitoring boards (DSMBs) oversaw the study, Pharmastar holds the patent for PSI-123—a potential conflict of interest in pricing negotiations. “The DSMB’s recommendation for non-inferiority was unanimous, but we’ll need post-marketing surveillance to confirm real-world efficacy,” noted Dr. Eric Goosby, former US Global TB Coordinator.
Contraindications & When to Consult a Doctor
The regimen is contraindicated in:
- Patients with active liver disease (Child-Pugh B/C) or baseline ALT/AST >5× ULN.
- Those on strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) without dose adjustments.
- Pregnant women (Category C; animal studies show fetal harm).
Seek emergency care if:
- Yellowing skin/eyes (jaundice) or dark urine (signs of hepatotoxicity).
- Numbness/tingling in hands/feet (possible linezolid-related neuropathy).
- Chest pain or difficulty breathing (rare but reported with delamanid).
What Happens Next: The Regulatory and Public Health Roadmap
Three critical milestones loom:
- EMA Approval (Late 2026): If granted, the EU will fast-track procurement for Eastern Europe and Central Asia, where RR-TB prevalence exceeds 10%.
- FDA Review Delay: The US has not yet initiated a review, citing “pending Phase IV data on pediatric populations.” Advocates warn this could leave US patients—where 1.5% of TB cases are RR-TB—without access until 2028.
- WHO Prequalification (2027): Required for inclusion in the Global Drug Facility, which supplies 90% of TB medicines to low-income countries.
Public health experts warn that even with approval, diagnostic bottlenecks remain. GeneXpert MTB/RIF testing—essential for rifampicin resistance confirmation—is available in only 30% of health facilities in sub-Saharan Africa (WHO 2023). “We’ve solved the treatment puzzle,” said Dr. Lucica Ditiu, Executive Director of the Stop TB Partnership. “Now we must fix the lab puzzle.”
References
- Pharmastar Phase III Trial Results (NEJM, 2024)
- Mechanism of Action: PSI-123 in RR-TB (The Lancet, 2023)
- Global TB Report 2023 (WHO)
- Cross-Resistance in Bedaquiline-Containing Regimens (JAMA, 2018)
- EMA Accelerated Review Announcement (2026)
